文献类型：期刊文献

英文题名：Network pharmacology and experimental study of Angelica sinensis and Astragalus membranaceus capsules in treating heart failure

作者：Wu, Xue[1,2,3,4];Liu, Ai[1,3];Lv, Xinfang[1,3,5];Zhi, Xiaodong[1,3,5];Zeng, Xiangting[4,6];Liu, Kai[1,3,5];Zhao, Xinke[1,3,5];Jiang, Bing[1];Jiang, HuGang[1,3];Li, Yingdong[1,3,5]

第一作者：Wu, Xue

通信作者：Li, YD[1];Li, YD[2];Li, YD[3]

机构：[1]Gansu Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Lanzhou, Peoples R China;[2]Lanzhou Univ, Hosp 2, Dept Cardiol, Lanzhou, Peoples R China;[3]Gansu Univ Chinese Med, Affiliated Hosp, Key Lab Prevent & Treatment Chron Dis Tradit Chine, Lanzhou, Peoples R China;[4]Lanzhou Univ, Clin Med Sch 2, Lanzhou, Peoples R China;[5]Gansu Univ Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China;[6]Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou, Peoples R China

第一机构：甘肃中医药大学中西医结合学院

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Lanzhou, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Affiliated Hosp, Key Lab Prevent & Treatment Chron Dis Tradit Chine, Lanzhou, Peoples R China;[3]corresponding author), Gansu Univ Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China.|[10735b845793de6ae2b30]甘肃中医药大学第二附属医院;[10735]甘肃中医药大学;[10735ed249c6606940a33]甘肃中医药大学中西医结合学院;

年份：2024

卷号：10

期号：20

外文期刊名：HELIYON

收录：;WOS:【SCI-EXPANDED(收录号:WOS:001772885800001)】；

基金：This is research that has been provided by NSFC (32060231, 82360926) , The Science and Technology Department of Gansu Province (21JR7RA399, 23JRRA1642) , the Major Science and Technology special project of Gansu Province (20ZD7FA002) , Gansu Provincial Education Department unveils the project (2021jyjbgs-03) ,Gansu Province Traditional Chinese Medicine Prevention and Treatment of Major Diseases Special Project (ZGKZD-2018-02) , The Lanzhou Science and Technology Bureau (2023-QN-191, 2018-ZD-1) , and the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (CY2021-BJ-A17) .

语种：英文

外文关键词：Network pharmacology; Molecular docking; Angelica sinensis and Astragalus; membranaceus capsule; Heart failure

摘要：Objective: This study explores the mechanism of AAC in intervening heart failure (HF) using network pharmacology, molecular docking, and in vitro experimental validation. Methods: The "active component-target" network and the "drug-disease target" protein interaction network were constructed using Cytoscape 3.9.0 and STRING Database. GO and KEGG enrichment analysis was performed using DAVID database. Then, the molecular docking of major compounds and target proteins was carried out using Autodock 1.5.7, and visualized with PyMOL 2.4.0 software. Finally, in vitro experimental validation was performed to explore the potential targets of AAC in treating HF. Results: The study revealed significant targets implicated in a variety of GO bioprocess programs and KEGG signaling networks. The primary chemicals to have strong binding ability with target proteins in molecular docking, with quercetin having the best binding energy with MAPK at -6.72 Kcal/Mol.Validation of cellular experiments showed that AAC might reduce the apoptosis that doxorubicin causes in AC16 cells by controlling the levels of PIK3CA, AKT1, and MAPK1. Conclusion: This study preliminarily reveals that AAC can treat HF through multiple components and multiple targets by using network pharmacology, molecular docking, and experimental validation.